NA
ASMB icon

NewEdge Advisors’s Assembly Biosciences ASMB Stock Holding History

NewEdge Advisors’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-846
Closed -$13.3K – 3961
2024
Q4 		$13.3K Buy
846
+84
+11% +$1.35K ﹤0.01% 2934
2024
Q3 		$11.5K Buy
+762
New +$11.6K ﹤0.01% 2892

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BGI
B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

NewEdge Advisors's ASMB Position: Q1 2025 in Review

NewEdge Advisors sold out of Assembly Biosciences (ASMB) in Q1 2025, closing a stake of 846 shares — an estimated $13.3K sold.

NewEdge Advisors first reported a position in ASMB in Q3 2024 and held it in 2 quarters. The position peaked at $13.3K in Q4 2024. 37 funds tracked by Wall St. Rank hold ASMB as of Q1 2025.

  • NewEdge Advisors reported no remaining Assembly Biosciences position as of Q1 2025 after selling out during the quarter.
  • NewEdge Advisors sold 846 Assembly Biosciences shares in Q1 2025, an estimated $13.3K.
  • NewEdge Advisors first reported a position in Assembly Biosciences in Q3 2024 and held it in 2 quarters.
  • NewEdge Advisors's Assembly Biosciences position peaked at $13.3K in Q4 2024.
  • 37 funds tracked by Wall St. Rank held Assembly Biosciences as of Q1 2025.

Based on NewEdge Advisors's 13F filing for Q1 2025, filed 15 May 2025.